搜索
 > 【4-1BB】重组蛋白信息

4-1BB信息

英文名称:Tumor necrosis factor receptor superfamily member 9
中文名称:肿瘤坏死因子受体超家族成员9
靶点别称:TNFRSF9,T-cell antigen ILA,ILA,T-Cell Antigen 4-1BB Homolog,4-1BB Ligand Receptor,CD137 Antigen,CDw137,CD137,Tumor Necrosis Factor Receptor Superfamily, Member 9,Tumor Necrosis Factor Receptor Superfamily Member 9,Homolog Of Mouse 4-1BB,Receptor Protein 4
上市药物数量:0
临床药物数量:17
最高研发阶段:临床二期

4-1BB Molecule Synonym Name

TNFRSF9,4-1BB,CD137,CDw137,ILA

4-1BB 分子背景

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

4-1BB 参考文献

4-1BB临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
GNC-038 GNC-038 临床一期 四川百利药业有限责任公司 实体瘤, 急性淋巴细胞白血病, 非霍奇金淋巴瘤 详情
RG-7827 RG-7827; FAP-4-1BBL; FAP-4-1BBL FP 临床一期 罗氏 肿瘤
MP-0310 AMG-506; MP-0310 临床一期 Molecular Partners Ag 肿瘤 详情
FS-120 FS-120 临床一期 F-Star 肿瘤, 转移癌 详情
INBRX-105 INBRX-105 临床一期 Inhibrx 肾细胞癌, 头颈部鳞状细胞癌, 胃癌, 移行细胞癌, 霍奇金病, 食道腺癌, 非霍奇金淋巴瘤, 非小细胞肺癌, 黑色素瘤 详情
ES101 ES101 临床一期 Inhibrx 肿瘤 详情
CTX-471 CTX-471 临床一期 Compass Therapeutics 转移癌 详情
ATOR-1017 ATOR-1017 临床一期 Alligator Bioscience 肿瘤, 转移癌 详情
ADG-106 ADG-106 临床二期 天演药业(苏州)有限公司 非霍奇金淋巴瘤 详情
Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) 临床一期 雅科生物科技 多发性骨髓瘤
MCLA-145 MCLA-145 临床一期 Incyte Corp, Merus 肿瘤 详情
GEN-1046 GEN1046; PD-L1x4-1BB; DuoBody-PD-L1x4-1BB 临床二期 Biontech Se, Genmab 实体瘤, 头颈部鳞状细胞癌, 移行细胞癌, 三阴性乳腺肿瘤, 子宫内膜样癌, 非小细胞肺癌, 宫颈癌 详情
AGEN-2373 AGEN-2373 临床一期 Agenus Inc 肿瘤 详情
ND-021 ND-021; NM21-1480 临床二期 Numab Therapeutics Ag 实体瘤, 肿瘤 详情
PRS-343 PRS-343 临床一期 Pieris Pharmaceuticals 实体瘤, 胃癌, 膀胱癌, 乳腺癌 详情
LVGN-6051 LVGN-6051 临床一期 礼进生物医药科技有限公司 肿瘤 详情
Urelumab BMS-66513; BMS-663513 临床二期 百时美施贵宝 B-细胞淋巴瘤, 头颈癌, 实体瘤, 肿瘤, 多发性骨髓瘤, 结直肠癌, 非霍奇金淋巴瘤, 黑色素瘤, 非小细胞肺癌, 慢性淋巴细胞白血病 详情
Utomilumab PF-2566; PF-5082566; PF-05082566 临床二期 辉瑞制药有限公司 卵巢癌, B-细胞淋巴瘤, 实体瘤, 头颈部鳞状细胞癌, 肾细胞癌, 肿瘤, 弥漫性大B-细胞淋巴瘤, 乳腺癌, 滤泡中心淋巴瘤, 结直肠癌, 口咽肿瘤, 非霍奇金淋巴瘤, 鳞状细胞癌, 非小细胞肺癌, 黑色素瘤 详情
ABL-503 ABL-503 Abl Bio Inc
Delolimogene mupadenorepvec LOAd-703 临床二期 Lokon Pharma, Uppsala University 胆管癌, 卵巢癌, 胰腺癌, 结直肠癌, 黑色素瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定